HAMBURG, Germany -- Faster-acting insulin aspart was safe for pregnant women with type 1 or 2 diabetes and resulted in fewer events of hypoglycemia, the randomized CopenFast trial found. The mean ...
The FDA approved insulin-aspart-szjj (Merilog) as the first rapid-acting insulin biosimilar product to treat adults and children with diabetes, the agency announced Friday. Like its reference ...
Please provide your email address to receive an email when new articles are posted on . Young children with type 1 diabetes had similar glycemic outcomes using fast-acting insulin aspart vs. standard ...
Merilog, a biosimilar to Novolog, offers a more affordable insulin option for type 2 diabetes patients, enhancing treatment accessibility. The GEMELLI-1 trial confirmed Merilog's noninferiority to the ...
COPENHAGEN, Jan 8 (Reuters) - Denmark's Novo Nordisk (NOVOb.CO), opens new tab said on Monday its COMBINE 3 phase 3a drug trial had shown that a weekly injection of IcoSema was superior in controlling ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results